文献速递基础与转化研究流行病学与生物统计医学人工智能与信息学

基于DNA液体活检预测癌症相关静脉血栓栓塞症

DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism.
PubMed 文献 · Nat Med · 2024-08-15

真实世界数据显示ctDNA阳性患者抗凝与较低VTE发生率相关,阴性患者未见获益,但需前瞻性随机干预研究确认临床效用。

要点

  • ctDNA检出与癌症相关VTE风险独立相关,不受临床和影像学特征影响。
  • 液体活检机器学习模型预测VTE的c指数在发现、验证和泛化队列分别为0.74、0.73和0.67,均优于Khorana评分。
  • 真实世界中ctDNA阳性患者抗凝与较低VTE发生率相关(校正HR=0.50),阴性患者未见获益。

核心结论

  • 液体活检可能改善基于临床参数的VTE风险分层,但需前瞻性随机干预研究确认其指导癌症患者抗凝的临床效用。

研究设计与样本

  • 研究分析三个血浆测序队列:泛癌发现队列4141例非小细胞肺癌(NSCLC)或乳腺癌、胰腺癌及其他癌症患者;前瞻性验证队列1426例相同癌种患者;国际泛化队列463例晚期NSCLC患者。
  • 另分析真实世界数据中ctDNA阳性2522例和阴性1619例患者抗凝与VTE发生率的关联。

主要发现

  • ctDNA检出与VTE独立相关,不受临床和影像学特征影响。
  • 基于液体活检数据的机器学习模型预测VTE的c指数在发现、验证和泛化队列分别为0.74、0.73和0.67,Khorana评分分别为0.57、0.61和0.54。
  • 真实世界数据中,ctDNA阳性患者抗凝与较低VTE发生率相关(n=2522,校正HR=0.50,95%CI:0.30-0.81)。
  • 真实世界数据中,ctDNA阴性患者抗凝未获益(n=1619,校正HR=0.89,95%CI:0.40-2.0)。

临床怎么用

  • 作者认为液体活检可能改善基于临床参数的VTE风险分层(原文结论为may improve)。
  • 作者指出需前瞻性随机干预研究确认液体活检指导癌症患者抗凝的临床效用。

局限性

  • 原文指出需前瞻性随机干预研究确认液体活检指导癌症患者抗凝的临床效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cancer-associated venous thromboembolism (VTE) is a major source of oncologic cost, morbidity and mortality. Identifying high-risk patients for prophylactic anticoagulation is challenging and adds to clinician burden. Circulating tumor DNA (ctDNA) sequencing assays ('liquid biopsies') are widely implemented, but their utility for VTE prognostication is unknown. Here we analyzed three plasma sequencing cohorts: a pan-cancer discovery cohort of 4,141 patients with non-small cell lung cancer (NSCLC) or breast, pancreatic and other cancers; a prospective validation cohort consisting of 1,426 patients with the same cancer types; and an international generalizability cohort of 463 patients with advanced NSCLC. ctDNA detection was associated with VTE independent of clinical and radiographic features. A machine learning model trained on liquid biopsy data outperformed previous risk scores (discovery, validation and generalizability c-indices 0.74, 0.73 and 0.67, respectively, versus 0.57, 0.61 and 0.54 for the Khorana score). In real-world data, anticoagulation was associated with lower VTE rates if ctDNA was detected (n = 2,522, adjusted hazard ratio (HR) = 0.50, 95% confidence interval (CI): 0.30-0.81); ctDNA- patients (n = 1,619) did not benefit from anticoagulation (adjusted HR = 0.89, 95% CI: 0.40-2.0). These results provide preliminary evidence that liquid biopsies may improve VTE risk stratification in addition to clinical parameters. Interventional, randomized prospective studies are needed to confirm the clinical utility of liquid biopsies for guiding anticoagulation in patients with cancer.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Jee J, Brannon AR, Singh R, et al. DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism. Nat Med. 2024. PMID: 39147831. doi:10.1038/s41591-024-03195-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。